This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Izumikawa, K.
Right arrow Articles by Kohno, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izumikawa, K.
Right arrow Articles by Kohno, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1998, p. 698-699, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Activities of Quinupristin-Dalfopristin and the Streptogramin RPR 106972 against Mycoplasma pneumoniae

Koichi Izumikawa,1,* Yoichi Hirakata,1 Toshiyuki Yamaguchi,1 Ryoji Yoshida,2 Hironori Tanaka,2 Hiromu Takemura,3 Shigefumi Maesaki,2 Kazunori Tomono,2 Mitsuo Kaku,3 Kin-Ichi Izumikawa,4 Shimeru Kamihira,1 and Shigeru Kohno2

Department of Laboratory Medicine1 and Second Department of Internal Medicine,2 Nagasaki University School of Medicine, Nagasaki 852, Department of Microbiology, St. Marianna University School of Medicine, Kawasaki 211,3 and Izumikawa Hospital, Nagasaki 859-15,4 Japan

Received 4 August 1997/Returned for modification 22 October 1997/Accepted 15 December 1997

The in vitro activities of quinupristin-dalfopristin and streptogramin RPR 106972 were determined with 44 strains of Mycoplasma pneumoniae and compared to those of macrolides, minocycline, and quinolones. All isolates tested were highly susceptible to macrolides and to quinupristin-dalfopristin (MIC at which 90% of the isolates are inhibited [MIC90], 0.0625 µg/ml), followed by RPR 106972 (MIC90, 0.5 µg/ml), quinolones, and minocycline.

* Corresponding author. Mailing address: Department of Laboratory Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852, Japan. Phone: 81 (95)-849-7420. Fax: 81 (95)-849-7422. E-mail: peaton-ngs{at}umin.u-tokyo.ac.jp.

Antimicrobial Agents and Chemotherapy, March 1998, p. 698-699, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kenny, G. E., Cartwright, F. D. (2001). Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones. Antimicrob. Agents Chemother. 45: 2604-2608 [Abstract] [Full Text]  
  • Yamaguchi, T., Hirakata, Y., Izumikawa, K., Miyazaki, Y., Maesaki, S., Tomono, K., Yamada, Y., Kamihira, S., Kohno, S. (2000). In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniae in Japan. Antimicrob. Agents Chemother. 44: 1381-1382 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»